EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects

Shumao Ni, Sheng Ma, Yingying Yu, Zhenwen Yu, Yujia Zhu, Xiaofen Sun, Lin Li, Caixia Sun, Hui Wang, Peng Peng, Zheming Gu, Hua Zhang und 3 weitere

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00486-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in R&D, 2024. Verfasst von Shumao Ni und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Healthy Volunteers, Biotransformation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TransThera Sciences (Nanjing), Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsHealthy VolunteersBiotransformationHumansMaleAdultYoung AdultFecesAdministration, OralHalf-LifeCarbon RadioisotopesPyridinesTriazoles

Substanzen

Protein Kinase InhibitorsGLPG0634Carbon RadioisotopesPyridinesTriazoles

Autor:innen und Institutionen

  • Department of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
  • Department of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute for Interdisciplinary Drug Research and Translational Sciences, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
  • Value Pharmaceutical Services Co. Ltd,, Nanjing, China.
  • Department of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China. miaolysuzhou@163.com.
  • Institute for Interdisciplinary Drug Research and Translational Sciences, College of Pharmaceutical Sciences, Soochow University, Suzhou, China. miaolysuzhou@163.com.

Förderung

  • TransThera Sciences (Nanjing), Inc.

Zitieren

APA

Ni, S., Ma, S., Yu, Y., Yu, Z., Zhu, Y., Sun, X., Li, L., Sun, C., Wang, H., Peng, P., Gu, Z., Zhang, H., Wu, F., Miao, L., & Fan, J. (2024). Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects. Drugs in R&D. https://doi.org/10.1007/s40268-024-00486-2

Vancouver

Ni S, Ma S, Yu Y, Yu Z, Zhu Y, Sun X, et al. Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects. Drugs in R&D. 2024. doi:10.1007/s40268-024-00486-2

BibTeX
@article{Ni2024,
  author = {Ni, Shumao and Ma, Sheng and Yu, Yingying and Yu, Zhenwen and Zhu, Yujia and Sun, Xiaofen and Li, Lin and Sun, Caixia and Wang, Hui and Peng, Peng and Gu, Zheming and Zhang, Hua and Wu, Frank and Miao, Liyan and Fan, Jean},
  title = {Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00486-2}
}
Kostenlos starten →